Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310290) titled 'Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks' on Dec. 16, 2025.
Study Type: Observational
Primary Sponsor: AbbVie
Condition:
Migraine
Recruitment Status: Not recruiting
Date of First Enrollment: December 17, 2025
Target Sample Size: 189
To know more, visit https://clinicaltrials.gov/study/NCT07310290
Disclaimer: Curated by HT Syndication....